Advertisement

Topics

Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis

07:00 EST 6 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory appr...

Other Sources for this Article

Investors:
Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-341-6108
or
Eric Rojas, 617-961-7205
or
Zach Barber, 617-341-6470
or
Media:
mediainfo@vrtx.com
US: 617-341-6992
Europe & Australia: +44 20 3204 5275

NEXT ARTICLE

More From BioPortfolio on "Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis"

Advertisement
Quick Search
Advertisement
Advertisement